BioSpace News Archive

Dr. Ryan Lanier, Ph.D., Associate Director, Consulting Unit at Analgesic Solutions will present “A Systematic Approach to Meeting Regulatory Requirements for Evaluating Potentially Abuse-Related Events in Clinical Trials” at the 5th Annual Human Abuse Liability Testing & Market Access Conference on Tuesday November 6th in Herndon, VA.

Now offering Vancomycin HCl, USP 10 g and 1 g lyophilized powder in the United States market.

Valens GroWorks Corp. is pleased to announce that it has entered into a multi-year cannabis extraction services agreement (the “Agreement”) with GTEC Holdings

Following an Extraordinary Meeting of Shareholders today, it was announced that ChemChina has appointed two additional Directors to the Board of Syngenta. Following these appointments the Board comprises six ChemChina appointed Directors and four Independent Directors.

Preliminary Quarterly Revenue Increase of 215-219% Comparable to 2017 Third Quarter

Easterly Government Properties, Inc. announced today that it has agreed to acquire a 50,978-square foot Drug Enforcement Administration (DEA) laboratory located in Upper Marlboro, Maryland (“DEA - Upper Marlboro”).

Sage Therapeutics today announced that, on November 1, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 15,400 shares of its common stock to 12 new employees under Sage’s 2016 Inducement Equity Plan.

Aurora secures right to increase ownership to 40% of Choom at $2.75 per common share

SpringWorks Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for PD-0325901, an investigational, oral, small molecule selective inhibitor of MEK1 and MEK2, for the treatment neurofibromatosis type 1.

Only 31 percent of REWIND trial participants had established CV disease